Skip to main content
TipRanks
Go Ultimate75% OFF

Novavax (0A3S) Stock Statistics & Valuation Metrics

16 Followers

Total Valuation

Novavax has a market cap or net worth of $1.31B. The enterprise value is $1.46B.

Market Cap
$1.31B
Enterprise Value
$1.46B

Share Statistics

Novavax has 165,009,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
165,009,000
Owned by Insiders
0.58%
Owned by Institutions
61.77%

Financial Efficiency

Novavax’s return on equity (ROE) is -3.45 and return on invested capital (ROIC) is 78.00%.

Return on Equity (ROE)
-3.45
Return on Assets (ROA)
0.37
Return on Invested Capital (ROIC)
78.00%
Return on Capital Employed (ROCE)
0.79
Revenue Per Employee
1.50M
Profits Per Employee
587.85K
Employee Count
749
Asset Turnover
0.95
Inventory Turnover
6.16

Valuation Ratios

The current PE Ratio of Novavax is -17.33. Novavax’s PEG ratio is 0.27.

PE Ratio
-17.33
PS Ratio
3.19
PB Ratio
-6.06
Price to FCF
-5.34
Price to Operating Cash Flow
-5.44
PEG Ratio
0.27

Income Statement

In the last 12 months, Novavax had revenue of 1.12B and earned 440.30M in profits. Earnings per share was 2.72.

Revenue
1.12B
Gross Profit
1.05B
Operating Income
563.27M
Pretax Income
442.17M
Net Income
440.30M
EBITDA
492.33M
Earnings Per Share (EPS)
2.72

Cash Flow

In the last 12 months, operating cash flow was -241.54M and capital expenditures -4.96M, giving a free cash flow of -246.50M billion.

Operating Cash Flow
-241.54M
Free Cash Flow
-246.50M
Free Cash Flow per Share
-1.49

Dividends & Yields

Novavax pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-18.77%
Earnings Yield
-5.84%

Stock Price Statistics

Beta
0.81
52-Week Price Change
17.71%
50-Day Moving Average
10.54
200-Day Moving Average
9.35
Relative Strength Index (RSI)
34.93
Average Volume (3m)
117.11K

Important Dates

Novavax upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 05, 2026
Next Earnings Date
Mar 04, 2027
Ex-Dividend Date
―

Financial Position

Novavax as a current ratio of 2.13, with Debt / Equity ratio of -194.76%

Current Ratio
2.13
Quick Ratio
2.10
Debt to Market Cap
0.22
Net Debt to EBITDA
0.02
Interest Coverage Ratio
24.98

Taxes

In the past 12 months, Novavax has paid 1.86M in taxes.

Income Tax
1.86M
Effective Tax Rate
0.00

Enterprise Valuation

Novavax EV to EBITDA ratio is -38.69, with an EV/FCF ratio of -5.62.

EV to Sales
3.37
EV to EBITDA
-38.69
EV to Free Cash Flow
-5.62
EV to Operating Cash Flow
-5.74

Balance Sheet

Novavax has $622.36M in cash and marketable securities with $295.26M in debt, giving a net cash position of $327.10M billion.

Cash & Marketable Securities
$622.36M
Total Debt
$295.26M
Net Cash
$327.10M
Net Cash Per Share
$1.98
Tangible Book Value Per Share
-$1.99

Margins

Gross margin is 77.25%, with operating margin of -19.58%, and net profit margin of -18.64%.

Gross Margin
77.25%
Operating Margin
-19.58%
Pretax Margin
-17.47%
Net Profit Margin
-18.64%
EBITDA Margin
-8.70%
EBIT Margin
-12.17%

Analyst Forecast

The average price target for Novavax is $13.60, which is 11.43% higher than the current price. The consensus rating is Neutral

Price Target
$13.60
Price Target Upside
70.40% Upside
Analyst Consensus
Neutral
Analyst Count
5
Revenue Growth Forecast
-61.33%
EPS Growth Forecast
-121.87%

Scores

Smart Score
8
AI Score
―